ANDA Submissions Drop To Start FY 2021, Perhaps Forced Down By COVID-19
Executive Summary
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
You may also be interested in...
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
ANDA Sponsors Could Lose Exclusivity Because COVID-19 Prevented An Inspection … Or Not
US FDA will determine on a case-by-case basis whether its inability to inspect a facility because of the pandemic could result in 180-day exclusivity forfeiture for first generic filers.